Evaluation of romosozumab’s effects on bone marrow adiposity in postmenopausal osteoporotic women: results from the FRAME bone biopsy sub-study
Authors' conclusion
In conclusion, based on the analysis of a small number of biopsies, no effect of romosozumab on bone marrow adiposity of iliac crest was identified after 2 and 12 months suggesting that the modeling-based formation observed at month 2 was not due to a preferential commitment of the precursor to osteoblast over adipocyte cell lines but may result from a reactivation of bone lining cells and from a progenitor pool independent of the marrow adipocyte population.
Study context
- Population
- Postmenopausal women with osteoporosis in the FRAME biopsy sub-study
- Comparison
- Romosozumab vs placebo
- Primary endpoint
- Marrow adiposity in transiliac bone biopsies: total adipocyte area, number and density on total cancellous bone area
- Follow-up
- Months 2 or 12
Methodological detailsbone biopsy sub-study, placebo-controlled, transiliac bone biopsies at months 2 or 12
- Bone biopsy sub-study
- Placebo-controlled
- Transiliac bone biopsies at months 2 or 12
Primary result
As reported in the abstract
- No significant difference in total adipocyte area, number or density between placebo and romosozumab at months 2 and 12; no difference between 2 and 12 months
- Small number of biopsies
Further findings
Adipocyte size and shape (mean area, perimeter, min and max diameters, aspect ratio) · 2 or 12 months
- Romosozumab did not modify adipocyte size or shape
Relationship of adipocyte parameters with dynamic bone formation parameters
- No relationship evidenced
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →